The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Lorabid     (6R,7S)-7-[[(2R)-2-amino-2- phenyl...

Synonyms: loracarbef, Loracarbefum, CHEMBL1013, SureCN34153, CHEBI:47544, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of loracarbef


Psychiatry related information on loracarbef


High impact information on loracarbef


Chemical compound and disease context of loracarbef


Biological context of loracarbef


Anatomical context of loracarbef

  • Loracarbef, a member of the carbacephem class of beta-lactam antibiotics, was tested in randomized, double-blind, parallel studies for the treatment of uncomplicated urinary tract infections (UTIs) [5].
  • Peripheral blood mononuclear cells were isolated from each patient and were exposed to cefaclor, loracarbef, and the metabolites of each generated with phenobarbital-induced murine hepatic microsomes [18].
  • Both cephalexin and loracarbef are transported by this mechanism into the human intestinal Caco-2 cell line [19].
  • On days 7 and 14 of therapy, sputum loracarbef concentrations were similar 4 h after the morning dose (0.23 mg/L following 200 mg; 0.35 mg/L after 400 mg) [20].
  • 1. The stereoselective transport of beta-lactam antibiotics has been investigated in the human intestinal epithelial cell line, Caco-2, by use of D- and L-enantiomers of cephalexin and loracarbef as substrates [21].

Associations of loracarbef with other chemical compounds


Gene context of loracarbef

  • Loracarbef (LY163892), a member of the class of beta-lactam antibiotics known as carbacephems, is characterized by a high level of chemical stability and a broad spectrum of antibacterial activity that persists in the presence of beta-lactamase [25].
  • Data analyzed from subjects with various degrees of renal dysfunction who were given single oral doses of loracarbef indicated a linear relationship between creatinine clearance (CLCR) and plasma clearance [CLP (L/hr) = 0.106.CLCR (ml/min/1.73 m2)] [14].
  • Pre-exposure to loracarbef resulted in increased susceptibility of E. coli and H. influenzae type b to the bactericidal activity of antiserum, but exposure to loracarbef or daptomycin did not modify serum sensitivity of S. aureus [16].
  • Mechanism and kinetics of transcellular transport of a new beta-lactam antibiotic loracarbef across an intestinal epithelial membrane model system (Caco-2) [26].
  • In vitro activity of loracarbef against TEM extended-spectrum beta-lactamase-producing Escherichia coli strains and its interaction with the enzymes [27].

Analytical, diagnostic and therapeutic context of loracarbef


  1. In vitro activity of loracarbef and effects of susceptibility test methods. Doern, G. Am. J. Med. (1992) [Pubmed]
  2. Acute bronchitis: results of U.S. and European trials of antibiotic therapy. Dere, W.H. Am. J. Med. (1992) [Pubmed]
  3. Loracarbef (LY163892) in the treatment of acute exacerbations of chronic bronchitis: results of U.S. and European comparative clinical trials. Zeckel, M.L. Am. J. Med. (1992) [Pubmed]
  4. Efficacy and safety of loracarbef in the treatment of pneumonia. Hyslop, D.L. Am. J. Med. (1992) [Pubmed]
  5. Antibiotic therapy for urinary tract infections. Iravani, A., Bischoff, W. Am. J. Med. (1992) [Pubmed]
  6. Comparison of loracarbef (LY163892) versus amoxicillin in the treatment of bronchopneumonia and lobar pneumonia. Müller, O., Wettich, K. Infection (1992) [Pubmed]
  7. The safety profile of loracarbef: clinical trials in respiratory, skin, and urinary tract infections. Therasse, D.G. Am. J. Med. (1992) [Pubmed]
  8. Pharmacokinetic profile of loracarbef. DeSante, K.A., Zeckel, M.L. Am. J. Med. (1992) [Pubmed]
  9. Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection model. Cappelletty, D.M., Rybak, M.J. Antimicrob. Agents Chemother. (1996) [Pubmed]
  10. Comparative evaluation of loracarbef and amoxicillin-clavulanate for acute otitis media. Gan, V.N., Kusmiesz, H., Shelton, S., Nelson, J.D. Antimicrob. Agents Chemother. (1991) [Pubmed]
  11. In-vitro activity of cefprozil (BMY 28100) and loracarbef (LY 163892) against pathogens obtained from middle ear fluid. Arguedas, A.G., Arrieta, A.C., Stutman, H.R., Akaniro, J.C., Marks, M.I. J. Antimicrob. Chemother. (1991) [Pubmed]
  12. The effects of low concentrations of antibiotics on epithelial damage caused by non-typable Haemophilus influenzae and bacterial morphology. Tsang, K.W., Rutman, A., Kanthakumar, K., Palmer, A., Roberts, D., Tillotson, G., Cole, P.J., Wilson, R. J. Antimicrob. Chemother. (1995) [Pubmed]
  13. Loracarbef (LY163892) versus amoxicillin/clavulanate in bronchopneumonia and lobar pneumonia. Hyslop, D.L., Jacobson, K., Guerra, F.J. Clinical therapeutics. (1992) [Pubmed]
  14. Effects of renal dysfunction on the pharmacokinetics of loracarbef. Therasse, D.G., Farlow, D.S., Davidson, R.L., Quadracci, L.J., Hatcher, B.L., Cerimele, B.J., DeSante, K.A. Clin. Pharmacol. Ther. (1993) [Pubmed]
  15. Structures of ceftazidime and its transition-state analogue in complex with AmpC beta-lactamase: implications for resistance mutations and inhibitor design. Powers, R.A., Caselli, E., Focia, P.J., Prati, F., Shoichet, B.K. Biochemistry (2001) [Pubmed]
  16. Influence of subinhibitory concentrations of loracarbef (LY 163892) and daptomycin (LY 146032) on bacterial phagocytosis, killing and serum sensitivity. Tripodi, M.F., Adinolfi, L.E., Utili, R., Marrone, A., Ruggiero, G. J. Antimicrob. Chemother. (1990) [Pubmed]
  17. Comparative bioavailability of loracarbef chewable tablet vs. oral suspension in children. Abdel-Rahman, S.M., Blowey, D.L., Kauffmann, R.E., Kearns, G.L. Pediatr. Infect. Dis. J. (1998) [Pubmed]
  18. Serum sickness-like reaction to cefaclor: lack of in vitro cross-reactivity with loracarbef. Kearns, G.L., Wheeler, J.G., Rieder, M.J., Reid, J. Clin. Pharmacol. Ther. (1998) [Pubmed]
  19. Structure-activity relationship of carbacephalosporins and cephalosporins: antibacterial activity and interaction with the intestinal proton-dependent dipeptide transport carrier of Caco-2 cells. Snyder, N.J., Tabas, L.B., Berry, D.M., Duckworth, D.C., Spry, D.O., Dantzig, A.H. Antimicrob. Agents Chemother. (1997) [Pubmed]
  20. Sputum and serum pharmacokinetics of loracarbef (LY163892) in patients with chronic bronchial sepsis. Hill, S.L., Bilton, D., Johnson, M.M., Pye, A., Mitchell, J.L., Stockley, R.A. J. Antimicrob. Chemother. (1994) [Pubmed]
  21. Stereoselective uptake of beta-lactam antibiotics by the intestinal peptide transporter. Wenzel, U., Thwaites, D.T., Daniel, H. Br. J. Pharmacol. (1995) [Pubmed]
  22. Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute purulent bacterial bronchitis. Dere, W.H., Farlow, D., Therasse, D.G., Jacobson, K.D., Guerra, F.J. Clinical therapeutics. (1992) [Pubmed]
  23. Pharmaceutical properties of loracarbef: the remarkable solution stability of an oral 1-carba-1-dethiacephalosporin antibiotic. Pasini, C.E., Indelicato, J.M. Pharm. Res. (1992) [Pubmed]
  24. Loracarbef (LY163892) vs. penicillin VK in the treatment of streptococcal pharyngitis and tonsillitis. Disney, F.A., Hanfling, M.J., Hausinger, S.A. Pediatr. Infect. Dis. J. (1992) [Pubmed]
  25. Loracarbef (LY163892) versus cefaclor in the treatment of bacterial skin and skin-structure infections in an adult population. McCarty, J., Ruoff, G.E., Jacobson, K.D. Am. J. Med. (1992) [Pubmed]
  26. Mechanism and kinetics of transcellular transport of a new beta-lactam antibiotic loracarbef across an intestinal epithelial membrane model system (Caco-2). Hu, M., Chen, J., Zhu, Y., Dantzig, A.H., Stratford, R.E., Kuhfeld, M.T. Pharm. Res. (1994) [Pubmed]
  27. In vitro activity of loracarbef against TEM extended-spectrum beta-lactamase-producing Escherichia coli strains and its interaction with the enzymes. Prinarakis, E.E., Tzouvelekis, L.S., Legakis, N.J. Chemotherapy. (1998) [Pubmed]
  28. Loracarbef (LY163892) versus cefaclor and norfloxacin in the treatment of uncomplicated pyelonephritis. Hyslop, D.L., Bischoff, W. Am. J. Med. (1992) [Pubmed]
  29. Loracarbef (LY163892) versus amoxicillin-clavulanate in the treatment of bacterial acute otitis media with effusion. Foshee, W.S. J. Pediatr. (1992) [Pubmed]
WikiGenes - Universities